First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore

First Subject Dosed in CANbridge Pharma CAN106 rare disease trial in Singapore for PNH and complement dysregulation diseases …
( read original story …)

---

Search your Hotel